Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.74 |
| ▸ | RAB9A | P51151 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359669 | 0.85 | MAPT (0.76) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4354253 | 0.81 | ALDH1A1 (0.78) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4354258 | 0.81 | ALDH1A1 (0.78) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| Bromide SCHEMBL4352442 | 0.80 | ALDH1A1 (0.76) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| Bromide SCHEMBL4352446 | 0.80 | ALDH1A1 (0.76) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4363209 | 0.77 | MAPT (1.00) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| Bromide SCHEMBL4362322 | 0.76 | MAPT (0.98) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4348932 | 0.74 | MAPT (0.69) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4348929 | 0.74 | MAPT (0.69) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4346511 | 0.74 | MAPT (0.63) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | claimed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1890695-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006122777-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | ABCB1, ABCG2, SLC5A2 | MAPT 1470/4885ALDH1A1 284/4885RAB9A 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.